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The implementation of novel therapeutic interventions has improved the survival rates of 
melanoma patients with metastatic disease. Nonetheless, only 33% of treated cases exhibit 
long term responses. Circulating tumor cell (CTC) measurements are currently of clinical 
value in breast, prostate and colorectal cancers. However, the clinical utility of melanoma 
CTCs (MelCTCs) is still unclear due to challenges that appear intrinsic to MelCTCs (i.e. 
rarity, heterogeneity) and a lack of standardization in their isolation, across research 
laboratories. Here, we review the latest developments, pinpoint the challenges in MelCTC 
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 15 
The implementation of novel therapeutic interventios has improved the survival rates of 16 
melanoma patients with metastatic disease. Nonetheless, only 33% of treated cases exhibit 17 
long term responses. Circulating tumor cell (CTC) measurements are currently of clinical 18 
value in breast, prostate and colorectal cancers. However, the clinical utility of melanoma 19 
CTCs (MelCTCs) is still unclear due to challenges that appear intrinsic to MelCTCs (i.e. 20 
rarity, heterogeneity) and a lack of standardization n their isolation, across research 21 
laboratories. Here, we review the latest developments, pinpoint the challenges in MelCTC 22 
isolation and address their potential role in melanoma management. 23 
Introduction 24 
Although melanoma is potentially curable when detect d in its earliest stages, it can 25 
metastasize to other tissues, drastically reducing survival rates [5]. Recent advances in 26 
immune- and targeted therapies have improved survival for metastatic cutaneous melanoma 27 
[35]. However, immunotherapies are highly toxic and effective in only a proportion of 28 
patients [40, 48, 57], and the majority of patients undergoing targeted therapies with MAPK 29 
inhibitors rapidly develop drug resistance [47, 49,54]. In order to overcome these challenges, 30 
biomarkers that can guide treatment decisions, monitor response to treatment and identify 31 















During the last decade, circulating tumor cells (CTCs) have received widespread 33 
attention as prognostic biomarkers [1, 18] (see Table I for the full list of terms). These cells 34 
are derived from primary and/or metastatic tumors and can be assessed at any point during 35 
disease course. Thus, their presence in peripheral blood can serve as a ‘‘liquid biopsy’’ of 36 
solid tumors, particularly when a biopsy cannot be undertaken due to inaccessibility of the 37 
tumor, or when multiple metastases are present in a patient. For increased clinical benefit, the 38 
analysis of these tumor-derived cells needs to assist with (a) disease prognosis, (b) prediction 39 
of clinical outcome to specific treatment, (c) patien -tailored, real time monitoring of 40 
response, (d) early detection of treatment resistance or recurrence and progression, and (e) 41 
discovery of new therapeutic targets and mechanisms of resistance. Additionally, the 42 
molecular characterization of these rare cells harbors significant information about cancer 43 
dissemination. 44 
The enrichment and detection of CTCs from patients is critically challenging, mainly due 45 
to the limited amount of blood sample available andthe very low concentration of these cells 46 
in peripheral blood. For melanoma, the difficulties are magnified because common CTC 47 
markers, such as EpCAM, used in CTC enrichment of epith lial cancers including breast and 48 
prostate cancers, are not commonly expressed by MelCTCs, since melanocytes originate 49 
from the neural crest and not the epithelium [19]. In addition, MelCTCs are a very 50 
heterogeneous population of cells [21, 25, 29], yetcurrent techniques used to enrich 51 
melanoma cells from blood do not commonly consider this factor, as their principle for CTC 52 
detection relies on the expression of only one or two markers. The isolation of MelCTCs 53 
usually follows two common steps: first, CTCs are enriched from the background of millions 54 
of blood cells and second, CTCs are detected and chara terized in the enriched fraction. 55 
Here we detail the progress of MelCTC isolation techniques, from the use of single 56 















also describe the clinical significance of current MelCTC studies, addressing the issues that in 58 
our informed opinion, hamper the progress of this research field. 59 
Melanoma CTC Enrichment Techniques 60 
Despite MelCTC heterogeneity [25, 29, 53], methods for their capture and enrichment 61 
have relied predominantly on the expression of one r two known cell surface markers 62 
(Figure 1). For example, immunomagnetic enrichment with magnetic beads coupled to 63 
antibodies against known melanoma-specific antigens has been used to enrich CTCs (positive 64 
selection). Alternate methods that deplete white blood cells (WBCs) using beads targeting 65 
common leukocyte (CD45 or CD34) antigens (negative sel ction) are also widely used [28, 66 
34, 44, 52]. 67 
The CellSearch™ system (Veridex LCC) involves immunomagnetic capture of CTCs 68 
followed by cancer-specific marker staining for CTC detection. This system is the only FDA-69 
approved CTC enumeration platform for breast, prostate and colorectal cancer, where 70 
EpCAM is used to capture CTCs followed by immunostaining with cytokeratin [2, 10-12]. 71 
This adhesion molecule has been described as important in tumor growth, EMT and 72 
metastasis [37, 38]; EpCAM is however, expressed exclusively in epithelial-derived 73 
neoplasms. A different CellSearch™ kit was therefor developed for MelCTC isolation, 74 
which captures CTCs expressing melanoma cell adhesion molecule (MCAM) from whole 75 
blood and detects CTCs by immunostaining with MCSP/CSGP4/HMW-MAA (melanoma-76 
associated chondroitin sulphate proteoglycan). 77 
Khoja and colleagues [28] used this melanoma specific CellSearch™ kit to detect CTCs 78 
in 101 metastatic melanoma patients, and found 0-36 CTCs/7.5 mL of blood prior to 79 
treatment, with 40% of patients having at least oneCTC. Similarly, Rao and colleagues, 80 
found 0 to 8,042 CTCs/7.5 mL of blood in 23% of thepatients (n = 44), with greater than 10 81 















by targeting only one marker for enrichment, other approaches increased the number of 83 
antigens targeted, in order to isolate a larger number of MelCTCs. 84 
Freeman and colleagues [21] found that using a combination of MCSP, MCAM, ATP-85 
binding cassette sub-family B member 5 (ABCB5), and cluster of differentiation 271 86 
(CD271) targeting antibodies, captured MelCTCs in a significantly higher proportion of 87 
metastatic melanoma patients than did the use of MCSP or MCAM alone. This finding 88 
demonstrated for the first time the high diversity of MelCTCs and improved the sensitivity of 89 
bead-based CTC enrichment compared with experiments tha  targeted single markers. In this 90 
study, patients from all stages showed significantly higher numbers of CTCs than controls 91 
(n=15), detecting at least 1 CTC/mL of blood in 73.9% of patients (range: 0-2.5 CTCs/mL of 92 
blood). However, despite this multimarker approach imed at improving the sensitivity of 93 
CTC capture, it still yielded low capture efficiency (34%) in spiking experiments [21], 94 
suggesting that only a few MelCTcs were being isolated. 95 
To improve capture efficiency, the herringbone-chip (HB-chip) technology has been 96 
developed. This device uses micro-vortices generated by herringbone-shaped grooves to 97 
direct cells toward channel walls coated with a combination of antibodies targeting 98 
melanoma-specific antigens. The combination of HB-chip technology with a pool of 12 99 
melanoma-specific antibodies for detection, allowed capture of CTCs (on average 8 100 
CTCs/2.5 mL) by immunostaining in 32/41 (79%) metastatic melanoma patients at various 101 
stages of treatment [36]. These results underscore the need for multiple markers to identify 102 
MelCTCs given their remarkable heterogeneity. Nevertheless, these methods are not able to 103 
capture all CTCs present within a patient, as those that do not express the antigen of interest 104 
are missed. 105 
To avoid capture bias, other studies have used negativ  selection procedures which 106 















magnetic separation. Systems such as EasySep™ or RosetteSep™ use this approach. Fusi 108 
and colleagues, using the EasySep™ method and detecting CTCs using gp100 and MLANA 109 
(melanoma antigen recognized by T cells 1) by flow cytometry, found 28/32 (87.5%) 110 
metastatic patients had CTCs with a median of 53 CTCs/10 mL of blood [22]. Using 111 
RosetteSep™, Girotti and colleagues successfully enriched CTCs and injected them into 112 
NSG mice to generate CDX models [23]. While the CTC quantities used to generate the 113 
models are unknown, it is likely that relatively large numbers of cells were isolated for 114 
successful tumor uptake. 115 
Although negative selection is advantageous for removing cells that do not express the 116 
most common melanoma markers, the purity of CTCs obtained in the enriched fraction is 117 
low, hampering their quantification and downstream nalysis. In fact, a spiking experiment 118 
comparing the recovery and purity of CD45 depletion with positive enrichment, or a 119 
combination of both methods, showed that the greatest recovery was found by using negative 120 
selection (58% recovery rate). However, the greatest purity of the CTC fraction was obtained 121 
by using the combination method (background reduced from 3x107 to 1.5x103of WBCs) [34]. 122 
To further improve CTC capture, alternative techniques have been developed recently 123 
that exploit the larger cell size of MelCTCs compared to WBCs. Although it has been shown 124 
that MelCTCs can have a diverse range of cell sizes [4, 41], most of the CTCs are thought to 125 
be larger (10-20 µm) than other blood components, such as RBCs (6-8 µm), leukocytes (7-12 126 
µm) or platelets (2-3 µm). Taking advantage of thisperceived difference in cell size, the 127 
“enrichment by size of epithelial tumor cells” (ISET®) technique was developed [58]. The 128 
ISET® system uses polycarbonate filters with 8 µm diameter circular pores for CTC 129 
enrichment and detection of cells trapped in filters. De Giorgi and colleagues detected CTCs 130 
in 29% and 62.5% of patients with primary invasive and metastatic melanoma respectively 131 















1 CTC/mL of blood [14]. However, this approach also detected benign circulating nevus cells 133 
[15], suggesting the inability of this assay to distinguish between benign nevus cells and 134 
melanoma cells. Alternatively, when using the same ISET enrichment technique, with CTCs 135 
defined by positive immunohistochemistry expression of S100 and negative expression for 136 
CD45 or CD144 (leucocyte and endothelial cell markers, respectively), 51/90 (57%) 137 
metastatic melanoma patients had detectable CTCs (1-44 CTCs/mL of blood) [29]. The low 138 
percentage of metastatic patients with high-burden isease found with CTCs, shows the 139 
unsuitability of this method for detecting all CTCs present in patients. This drove the 140 
combination of technologies that rely on physical properties of the MelCTCs with those 141 
detecting expression of specific surface markers. 142 
The CTC-iChip separates cells based on size using deterministic lateral displacement and 143 
inertial focusing followed by negative depletion. Using this chip, CTCs from two metastatic 144 
melanoma patients were successfully enriched and detected as positive by staining for the 145 
melanoma antigen recognized by T cells 1 (MART-1/MLANA) [41].  146 
The OncoQuick® system is another size-based technique that incorporates a filter for 147 
CTC separation in conjunction with density-based centrifugation [50]. Spiking experiments 148 
showed a ≥60% recovery rate of 4, 20, 100 and 500 spiked SkMel28 cells when assessed by 149 
qPCR amplification of cytokeratin 8 (KRT8) and 18 (KRT18) RNA. The SkMel28 cell line 150 
strongly expresses these intermediate filament proteins and KRT18 expression has been 151 
previously identified as an adverse prognostic factor in melanoma [8]. For melanoma CTCs, 152 
when transcript levels of MLANA, MIF (Macrophage Migration Inhibitory Factor), TYR, and 153 
MITF (Melanogenesis Associated Transcription Factor) were assessed by qPCR after 154 
OncoQuick® enrichment, results showed that about 1/3 of patients (mostly early-stage) 155 
expressed elevated levels of MIF and MLANA transcripts, in comparison with healthy 156 















early-stage patients with CTCs may be used to delineate those that would benefit from a more 158 
aggressive therapy at an earlier stage. 159 
Previous studies have found circulating tumor microemboli (CTM) or CTC clusters in 160 
the blood of melanoma patients, raising the idea that cells enter the bloodstream via collective 161 
cell migration, allowing them to survive shear stres and anoikis forces [29, 42]. Recently, the 162 
Cluster-Chip was developed to specifically isolate CTC clusters of two or more cells from 4 163 
mL of blood, independently of tumor-specific marker expression. This microchip technology 164 
relies on the strength of the cluster union and on their behavior when a flow speed is applied 165 
through a set of triangular pillars. Captured CTC clusters were identified and detected by 166 
immunostaining in 30% (~0.15 CTCs/mL) of 20 tested metastatic melanoma patients. 167 
Interestingly, no correlation was found between the number of CTC clusters and the number 168 
of single CTCs isolated (n = 19) [53]. 169 
While these methods have proven the ability to capture CTCs, clinical validation of their 170 
prognostic value in large clinical samples is still needed. 171 
Melanoma CTC Detection Methods 172 
While the above techniques have been developed to improve isolation of CTCs, 173 
optimization of detection methods is also required. Detection of MelCTCs without a previous 174 
enrichment step has been reported by Ruiz and colleagues [51], where the Epic Sciences 175 
platform detected MelCTCs from whole blood, using a p nel of seven anti-MCSP 176 
monoclonal antibodies. MCSP is a cell surface protein involved in melanoma proliferation, 177 
spreading and migration of cells and it is overexprssed in more than 90% of melanoma 178 
tumor tissue samples [6, 13]. Using this marker for detection, 1-250 CTCs were detected in 8 179 
mL of blood (0.5 to 371.5 CTCs/mL of blood) from 22/40 metastatic melanoma patients 180 
(55%). Interestingly, this method also enabled whole genome amplification and copy number 181 















PTEN, and amplifications of melanoma related genes, TERT, BRAF, KRAS and MDM2 183 
amongst others [51]. 184 
Most commonly, once CTCs are enriched by the techniques discussed above they are 185 
detected by methods that assess their morphology and/or protein expression using 186 
immunocytochemistry (ICC) or flow cytometry. In these techniques a cocktail of antibodies 187 
against cell surface or intracellular markers associated with melanocyte biology or melanoma 188 
pathogenesis [21, 25, 30, 55] are used to recognize the cells. Alternately, molecular 189 
approaches that detect RNA or DNA from enriched MelCTCs, by quantitative real-time PCR 190 
(qRT-PCR) [4, 39] or droplet digital PCR (ddPCR) [45], respectively, have been used for 191 
CTC detection and characterization. A new and promising method based on the presence of 192 
elevated telomerase activity commonly found in melanoma cells, is being trialed for CTC 193 
detection [61]. 194 
Based on our previous identification of heterogeneous MelCTCs [21], we recently 195 
developed a flow-cytometry multimarker approach to detect and analyze CTCs for the 196 
presence of melanoma-associated markers, such as MCSP and MCAM, in combination with 197 
melanoma stem cell markers, such as ABCB5, RANK (receptor activator of NF-κβ) and 198 
CD271 [25]. Using this approach we provided for thefirst time, a detailed insight into the 199 
diversity of MelCTCs within each patient, and showed that the prognostic utility of MelCTCs 200 
may not rely on the total count of CTCs but on the CTC subpopulations circulating within an 201 
individual. This study indicated that a high number of MelCTCs express melanoma-initiating 202 
or stem cell markers (ABCB5 and RANK) while only very low numbers of CTCs express 203 
melanoma markers MCSP and MCAM [25]. Importantly, the common expression of these 204 
melanoma-initiating markers by MelCTCs did not correlate with the expression of these 205 
markers in patient-matched tumors, where a low frequency of melanoma tumor cells positive 206 















melanoma, are derived from rare subpopulations of tumor cells which may have the ability to 208 
seed new metastases, and not from the bulk melanoma cells shaping the tumor [25]. 209 
Aya-Bonilla and colleagues [4] more recently interrogated for the first time, the 210 
enrichment of MelCTCs using spiral microfluidic technology [59, 60]. With this device, 211 
recovery rates of greater than 55% and a 2.5-3 log depletion of WBCs were observed in 212 
spiking experiments using melanoma cell lines with different cell sizes which represents an 213 
improvement to depletion rates similar to those obtained by the CTC-iChip [41]. After 214 
microfluidic enrichment of blood from 20 metastatic melanoma patients, MelCTCs were 215 
identified by flow cytometry, gene expression analysis and immunostaining, in 40%, 54% 216 
and 43% of cases, respectively. As found previously [21, 25, 29], MelCTCs showed diversity 217 
in their marker population with CTCs analyzed by flow cytometry most commonly 218 
expressing ABCB5 alone or in combination with RANK, a marker of treatment resistance. 219 
Gene expression analysis of the CTC-enriched fractions also detected transcripts of PAX3, 220 
alone or in combination with ABCB5 expression in 6 out of 7 metastatic melanoma patients 221 
positive for melanoma transcripts; transcripts of the melanocytic gene, MLANA, were 222 
detected in the remaining patient. MLANA, PAX3 and ABCB5 are highly expressed in 223 
melanoma tumors and have been described to play an important role in melanoma 224 
pathogenesis and resistance [17, 20, 43]. In this sudy, isolated CTCs were also characterized 225 
by multimarker immunostaining for intracellular melanocytic proteins gp100, S100 and 226 
MLANA (1-4 CTCs/ 8 mL of blood), which indicated that MelCTCs are also diverse in cell 227 
size (range: 13-21 µm) [4]. This study unmistakably confirmed the phenotypic and molecular 228 
heterogeneity of MelCTCs. 229 
Although great advances have been made in MelCTC isolat on (Figure 1; Table II), their 230 
quantification remains challenging given the low numbers of CTCs identified even when a 231 















limited knowledge of the spectrum of diverse MelCTCs. Studies are needed to investigate 233 
MelCTC phenotypes, their role in melanoma biology and prognosis as well as their 234 
differential pharmacodynamic responses to treatment [31]. 235 
Are CTCs of clinical utility in melanoma? 236 
Studies to date show CTCs are a suitable biomarker of disease status. Furthermore, 237 
monitoring the levels of CTCs before and during melanoma treatment has, in limited studies, 238 
been shown to be informative with respect to prognosis and therapy response in melanoma 239 
[25, 28, 31, 36, 46]. 240 
Using RT-PCR to detect transcripts in blood, Reid an colleagues showed that in 230 241 
patients, the presence of MLANA and ABCB5 transcripts were associated with disease 242 
recurrence and the expression of MCAM was significantly more common in patients with a 243 
poor treatment outcome [46]. Also, the presence of multiple melanoma markers in patient 244 
blood significantly correlated with their AJCC stage [32], and the detection of more than one 245 
marker at baseline and at any time during treatment administration was a negative prognostic 246 
factor for disease-free survival (DFS) and for overall survival (OS) [26]. 247 
Several studies using immunomagnetic enrichment have also shown that the number of 248 
MelCTCs is higher in the blood of patients with advnced disease [21, 36, 62]. Moreover, the 249 
number of CTCs was also shown to be associated with treatment failure and shorter median 250 
OS when ≥ 2 CTCs per 7.5 mL are found during the time that patients are receiving treatment 251 
[28, 44]. By contrast, a low CTC count at baseline (< 2 CTCs) or a decrease in CTCs after 252 
treatment initiation was associated with response to treatments and longer progression free 253 
survival (PFS) rates [31]. 254 
Recently, using flow cytometry to separate CTC subtypes, we showed that the presence 255 
of CTCs was associated with disease stage and PFS [25]. Interestingly, early-stage patients 256 















numbers of CTCs expressing a variety of markers. Additionally, patients with higher number 258 
of CTCs (>5 RANK+ cells) in 4 mL of blood had significantly lower PFS than those with 259 
fewer or no CTCs (<5 RANK+ cells) [25]. Importantly, we demonstrated that progn stic 260 
utility might be found not merely by using total CTs counts but by studying specific 261 
subpopulations of CTCs and response to therapy. Patients (n=16) who relapsed after targeted 262 
BRAF inhibitor therapy were most likely to exhibit greater numbers of RANK CTC subtypes. 263 
Conversely, the presence of CTCs expressing PD-L1 was associated with response to anti-264 
PD1 blockade [27]. 265 
New experiments with patient-derived xenografts (PDX) are providing new information 266 
that can inform treatment decisions for each patient. Particularly where tumors are 267 
inaccessible, CTC-derived xenografts (CDX) or in vitro growth of CTCs may provide a 268 
powerful tool for drug efficacy testing for each patient. Girotti and colleagues [23] have been 269 
successful in generating CDXs in 6 out of 21 cases (28.6%) and showed that CDX models 270 
established from advanced stage patients could aid in the prediction of patient responses to 271 
treatments [23]. While the isolation of only a few CTCs capable of developing xenografts 272 
may underestimate the tumor heterogeneity, these are xcellent first steps, addressing several 273 
of the issues surrounding the clinical benefit of CTC characterization, including the fact that 274 
CTCs that develop xenografts are capable of seeding metastases and therefore harbor 275 
significant information about the metastatic process. Additionally, further studies 276 
characterizing CTC subpopulations prior to or concurrently with injecting them into mice will 277 
provide crucial information about CTC phenotypes that are most likely to develop CDXs. 278 
Although CTCs quantification shows great potential, the role of MelCTCs in melanoma 279 
management is still under investigation. For example, the continued presence or an increase 280 
of MelCTCs after therapy initiation may suggest disea e progression. Contrarily, a decrease 281 















changes in CTC phenotype after treatment initiation may be an early indicator of the 283 
emergence of resistance, leading to an early change of therapy. Although these changes are 284 
difficult to assess when low numbers of MelCTCs are being isolated, these measurements 285 
could offer unique prognostic information. Furthermo e, MelCTCs could be tested for 286 
molecular evolution of tumors prior to therapy, to identify markers of intrinsic resistance; and 287 
during therapy, to identify the development of drug esistance to targeted therapies. 288 
There is also a need to evaluate the ability of CTC analysis to inform treatment decision 289 
in patients with AJCC stage III and resected stage IV melanomas, as there are now more 290 
clinical trials and FDA approved therapeutics for melanoma in stage III and stage IV [3, 35]. 291 
The lack of standardization and the variety of methodologies used for their isolation has 292 
hampered the ability to implement the analysis of MelCTCs into large clinical studies. 293 
Therefore, there is an urgent need to standardized protocols for MelCTC enrichment, 294 
detection, and quantification across different labor t ries. 295 
What additional isolation steps are required to identify the full spectrum of melanoma 296 
CTC subtypes and their prognostic potential? 297 
Melanoma CTCs are rare and very heterogeneous. The comprehension of their 298 
aggressiveness and their application in clinical settings is still limited by the capacity to 299 
successfully and routinely isolate viable heterogeneous CTCs from the majority of patients. 300 
New platforms that enable effective and repetitive solation of MelCTCs should be 301 
unbiased, which means that CTCs should be enriched and detected without relying on known 302 
expression of CTC markers, rather, methods should be based on broader traits of CTCs, such 303 
as physical properties (cell size, morphology, rigidity, nuclear/cytoplasm ratio). In addition, 304 
isolation methods should be highly efficient in enriching the vast majority of CTCs present in 305 
the blood at high purity (i.e. low WBC background). Moreover, methods should allow 306 















establishment of CTC-derived cell cultures and xenografts (CDX). Furthermore, methods are 308 
required that allow high throughput, are low cost and ccessible in both research and clinical 309 
environments. 310 
Integration of genomic and transcriptomic data from bulk tumors [7] together with 311 
single-cell RNA-seq of melanoma tumors [56] have reinforced the abundant diversity 312 
between and within melanoma tumors. Thus CTCs derived from such tumors would similarly 313 
carry heterogeneous features. However, the challenges in isolating all CTCs have 314 
significantly flawed the interrogation of the real genomic, transcriptomic and proteomic 315 
diversity of MelCTCs. 316 
Finding a system able to capture and detect CTCs independently of their cell marker 317 
characteristics is urgently needed in melanoma, and  few studies trialing this isolation 318 
approach have been reported [4, 14, 29, 41]. Advances remain hampered however by the 319 
uncertain biology of these cells, and the lack of optimal technologies along with robust 320 
standardization and validation of these technologies. 321 
Although challenging, studying the gene expression and mutational landscape of single 322 
MelCTCs, their relationship with tumor tissue cells and their connection with treatment 323 
response and resistance, will significantly increase the clinical value of this biomarker. 324 
Improvements along these lines will dramatically advance CTC use in the clinic. The recent 325 
implementation of devices capable of isolating viable and label-free MelCTCs paves the way 326 
for studies aimed at dissecting their real heterogeneity and the mechanisms underlying their 327 
role in melanoma spreading. Moreover, the isolation and study of MelCTC clusters will 328 
provide an insight into their role in melanoma progression and metastasis and in the tumor-329 
















In conclusion, a variety of isolation methods have be n developed in order to study the 332 
prognostic and predictive applications of CTCs in melanoma. Moving forward, the 333 
implementation of optimal isolation techniques allowing phenotypic, genomic and 334 
transcriptomic approaches is critical in order to unveil the diversity of MelCTCs and provide 335 
new insights into their clinical opportunities (Figure 2). The latest studies suggest that 336 
examining CTC subpopulations instead of quantifying CTCs, could significantly impact their 337 
clinical utility. However, the variety of subpopulations needs to be identified and clinical 338 
trials assessing the biomarker utility of these subpopulations needs to be undertaken to draw 339 
meaningful conclusions. Also, critical factors such as the time of blood collection (i.e., 340 
different time points), site of collection of blood sample [24], sample handling, transport and 341 
storage must not be overlooked and remains to be standardized. Although promising, 342 
MelCTC isolation and study still holds technological limitations that ought to be considered 343 
by MelCTC specialists worldwide to maximize their potential applications in clinical 344 
practice. 345 
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Figure Legends 570 
Figure 1. The most widely used circulating tumor cell enrichment, detection and molecular 571 
characterization technologies for melanoma and other cancers. NGS: next generation 572 
sequencing. DEP: dielectrophoresis. ddPCR: droplet digital polymerase chain reaction. FISH: 573 
fluorescence in situ hybridization. RT-PCR: real time polymerase chain reaction. 574 
Figure 2. Potential applications and clinical benefits of melanoma circulating tumor cells. 575 















Table I. List of terms. 577 
ABCB5 ATP binding cassette subfamily B member 5 
AJCC American Joint Committee on Cancer 
BRAF proto-oncogene B-Raf; v-Raf murine sarcoma viral oncogene homolog B 
CD144 VE-Cadherin 
CD271 
LNGFR (low-affinity nerve growth factor receptor) 
p75 NTR (neurotrophin receptor) 
CD34 cluster of differentiation 34 
CD45 cluster of differentiation 45 
CDKN2A cyclin-dependent kinase Inhibitor 2A 
CDX Cancer or CTC derived xenografts 
CNV copy number variation 
CTC circulating tumor cell 
CTM circulating tumor microemboli 
ddPCR droplet digital PCR 
EpCAM epithelial cell adhesion molecule 
FDA US Food and Drug Administration 
gp100 glycoprotein 100; melanocyte protein PMEL 
HB-chip herringbone-chip 
ICC immunocytochemistry 
ISET isolation by size of epithelial tumor cells 
KRAS proto-oncogene K-Ras; Kirsten rat sarcoma virus 
KRT18 Cytokeratin 18 
KRT8 Cytokeratin 8 
MAPK mitogen-activated protein kinase 
MCAM melanoma cell adhesion molecule 
MCSP/CSGP4/HMW-MAA melanoma-associated chondroitin sulphate proteoglycan 
MDM2 proto-oncogene MDM2 
MelCTC melanoma circulating tumor cells 
MIF macrophage migration inhibitory factor 
MITF microphthalmia-associated transcription factor 
MLANA/MART-1 melanoma antigen recognized by T cells 1 
NSG NOD scid gamma mice 
PAX3 paired box gene 3 
PD-1 programmed cell death protein 1 
PD-L1 programmed Death-ligand 1 
PDX patient derived xenografs 
PFS progression free survival 
PTEN phosphatase and tensin homolog 
RANK receptor activator of NF-κβ 
RBCs red blood cells 
TERT telomerase reverse transcriptase 
















Table II. Assessment of MelCTC enrichment and detection techniques. 579 








Relies on prior 














Relies on no marker 
expression by CTCs and 
high expression by 





Low specificity. Not 
commercially available. 
[41] 






















Low specificity. Limited 
studies. 
[4] 







Lack of biological 
characterization and 
clinical significance. Not 
commercially available. 
[53] 
     
MelCTC Detection Advantages Disadvantages References 
Immunocytochemistry 
Individual cell analysis. 
Common protocols used. Low 
cost. 
Time consuming. Low 








requires previous enrichment; 
limited number of markers. 
[22, 25, 33] 
qRT-PCR ost effective. High sensitivity. 
Biased CTC detection. 
Unclear specificity. Not 
quantifiable. 
[4, 16, 39] 
ddPCR High specificity. Cost effective. 
Sensitivity compromised by 
WBC background. Analysis 












































- This review discusses Melanoma CTCs (MelCTCs)  
- MelCTCs are promising liquid biopsy biomarkers in melanoma  
- They are heterogeneous with no common marker for their detection, unlike epithelial 
cancers. 
- Label-independent methods are preferred for isolation of diverse MelCTCs.  
- Identification of MelCTC subtypes provides significant clinical utility. 
